BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Docetaxel (HB1801) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Docetaxel (HB1801)\, from ClinicalTrials.
 gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06747338-2506@assetmemo.bio
DTSTAMP:20261121T004118Z
DTSTART;VALUE=DATE:20261216
DTEND;VALUE=DATE:20261217
SUMMARY:Docetaxel (HB1801): Phase 3 readout est. (NCT06747338)
DESCRIPTION:Docetaxel (HB1801)\, phase 3\, HER2-Positive Breast Cancer.\nSt
 udy: A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin 
 as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breas
 t Cancer\nEstimated primary completion: 16 December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/docetaxel-hb1801#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06747338
URL:https://assetmemo.bio/drug/docetaxel-hb1801#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06525350-2506@assetmemo.bio
DTSTAMP:20261121T004118Z
DTSTART;VALUE=DATE:20261225
DTEND;VALUE=DATE:20261226
SUMMARY:Docetaxel (HB1801): Phase 2 readout est. (NCT06525350)
DESCRIPTION:Docetaxel (HB1801)\, phase 2\, Non-Small Cell Lung Cancer.\nStu
 dy: A Study to Evaluate the Efficacy and Safety of the Combination of Glum
 etinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment o
 f MET-overexpressed Non-small Cell Lung Cancer\nEstimated primary completi
 on: 25 December 2026. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /docetaxel-hb1801#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06525350
URL:https://assetmemo.bio/drug/docetaxel-hb1801#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05582499-2506@assetmemo.bio
DTSTAMP:20261121T004118Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Docetaxel (HB1801): Phase 2 readout est. (NCT05582499)
DESCRIPTION:Docetaxel (HB1801)\, phase 2\, HER2-Positive Breast Cancer.\nSt
 udy: Fudan University Shanghai Cancer Center Breast Cancer Precision Platf
 orm Series Study- Neoadjuvant Therapy\nEstimated primary completion: 31 De
 cember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/docetaxe
 l-hb1801#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05582499
URL:https://assetmemo.bio/drug/docetaxel-hb1801#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07805135-2506@assetmemo.bio
DTSTAMP:20261121T004118Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Docetaxel (HB1801): Phase 3 readout est. (NCT07805135)
DESCRIPTION:Docetaxel (HB1801)\, phase 3.\nStudy: A Study of HB1801 Versus 
 Docetaxel (Taxotere®) in Patients With Advanced Breast Cancer\nEstimated 
 primary completion: 1 June 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/docetaxel-hb1801#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07805135
URL:https://assetmemo.bio/drug/docetaxel-hb1801#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07441460-2506@assetmemo.bio
DTSTAMP:20261121T004118Z
DTSTART;VALUE=DATE:20340807
DTEND;VALUE=DATE:20340808
SUMMARY:Docetaxel (HB1801): Phase 3 readout est. (NCT07441460)
DESCRIPTION:Docetaxel (HB1801)\, phase 3\, HER2-Positive Breast Cancer.\nSt
 udy: A Phase III Study of KN026 in Combination With HB1801 as Adjuvant The
 rapy for Resectable HER2-Positive Breast Cancer\nEstimated primary complet
 ion: 7 August 2034. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/d
 ocetaxel-hb1801#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07441460
URL:https://assetmemo.bio/drug/docetaxel-hb1801#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
